Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma.

doi:10.1038/s41591-020-0839-y

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma.

Nature medicine - 1 Jun 2020

Braun David A, Hou Yue, Bakouny Ziad, Ficial Miriam, Sant' Angelo Miriam, Forman Juliet, Ross-Macdonald Petra, Berger Ashton C, Jegede Opeyemi A, Elagina Liudmilla, Steinharter John, Sun Maxine, Wind-Rotolo Megan, Pignon Jean-Christophe, Cherniack Andrew D, Lichtenstein Lee, Neuberg Donna, Catalano Paul, Freeman Gordon J, Sharpe Arlene H, McDermott David F, Van Allen Eliezer M, Signoretti Sabina, Wu Catherine J, Shukla Sachet A, Choueiri Toni K

Abstract excerpt

PD-1 blockade has transformed the management of advanced clear cell renal cell carcinoma (ccRCC), but the drivers and resistors of the PD-1 response remain incompletely elucidated. Here, we analyzed 592 tumors from patients with advanced ccRCC enrolled in prospective clinical trials of treatment with PD-1 blockade by whole-exome and RNA sequencing, integrated with immunofluorescence analysis, to uncover the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antigen Presentation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antineoplastic Agents, Immunological

Share to Histone Demethylases

Share to Lymphocytes, Tumor-Infiltrating

Share to Nivolumab

Share to Tuberous Sclerosis Complex 1 Protein

Share to Ubiquitin Thiolesterase

Share to Von Hippel-Lindau Tumor Suppressor Protein

Source

Open in PubMed Open full text

Identifiers

PMID: 32472114
DOI: 10.1038/s41591-020-0839-y
PMCID: PMC7499153

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma.PMID 32472114Read ↗

Correlating Immune Cell Infiltration Patterns with Recurrent Somatic Mutations in Advanced Clear Cell Renal Cell Carcinoma.Semantic proximity Read ↗

Immune Phenotype-Genotype Associations in Primary Clear Cell Renal Cell Carcinoma and Matched Metastatic Tissue.Semantic proximity Read ↗

Whole genome sequencing refines stratification and therapy of patients with clear cell renal cell carcinomaSemantic proximity Read ↗

BAP1 and PTEN mutations shape the immunological landscape of clear cell renal cell carcinoma and reveal the intertumoral heterogeneity of T cell suppression: a proof-of-concept study.Semantic proximity Read ↗

Whole genome sequencing refines stratification and therapy of patients with clear cell renal cell carcinoma.Semantic proximity Read ↗

Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma.Semantic proximity Read ↗

Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signaturesSemantic proximity Read ↗

Prognostic Immunophenotyping Clusters of Clear Cell Renal Cell Carcinoma Defined by the Unique Tumor Immune MicroenvironmentSemantic proximity Read ↗

Exploration of the relationships between tumor mutation burden with immune infiltrates in clear cell renal cell carcinomaSemantic proximity Read ↗

DNA methylation is a key determinant of response to targeted and immune checkpoint therapies in metastatic renal cell carcinomaSemantic proximity Read ↗

Silencing of genes by promoter hypermethylation shapes tumor microenvironment and resistance to immunotherapy in clear-cell renal cell carcinomasSemantic proximity Read ↗

Spatiotemporal evolution of the clear cell renal cell carcinoma microenvironment links intra-tumoral heterogeneity to immune escapeSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.